<table-wrap id="T5" position="float"> 
 <label>Table 5</label>  
 <p>NCI60 cell lines with predicted active pathways by mutational analysis</p>  
 <table frame="hsides" rules="groups"> 
  <thead> 
   <tr> 
    <td align="left"> 
     <bold>
      Tumor Type
     </bold> </td>
    <td align="left"> 
     <bold>
      Ras
     </bold> </td>
    <td align="left"> 
     <bold>
      PI3K
     </bold> </td>
    <td align="left"> 
     <bold>
      Other Mutation
     </bold> </td>
    <td align="left"> 
     <bold>
      Not Tested
     </bold> </td> 
   </tr> 
  </thead> 
  <tbody> 
   <tr> 
    <td align="left"> 
     <bold>
      Breast
     </bold> </td>
    <td align="left">HS578T, MDA-MB231, MD-MB435</td>
    <td align="left">MCF7, T47,</td>
    <td align="left">-</td>
    <td align="left">MDA-N, BT549</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      CNS
     </bold> </td>
    <td align="left">-</td>
    <td align="left">SF295, SF359, SNB19, U251</td>
    <td align="left">SF268, SNB75</td>
    <td align="left">-</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      Colon
     </bold> </td>
    <td align="left">HCC2998, HCT116, HCT15, SW620, COLO205, HT29</td>
    <td align="left">KM12</td>
    <td align="left">-</td>
    <td align="left">-</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      Leukaemia
     </bold> </td>
    <td align="left">CCRF-CEM, RPMI-8226, HL60, MOLT4, K562</td>
    <td align="left">-</td>
    <td align="left">-</td>
    <td align="left">SR</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      Melanoma
     </bold> </td>
    <td align="left">SK-MEL2, LOXIMVI, M14, MALME-3M, SK-MEL28, SK-MEL5, UACC257, UACC62</td>
    <td align="left">-</td>
    <td align="left">-</td>
    <td align="left">-</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      Lung
     </bold> </td>
    <td align="left">A549, HOP62, NCI-H23, NCI-H460</td>
    <td align="left">-</td>
    <td align="left">EKVX, NCI-H226, NCI-H322, NCI-H522</td>
    <td align="left">HOP92</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      Ovarian
     </bold> </td>
    <td align="left">OVCAR5, OVCAR8</td>
    <td align="left">SKOW3, IGROV1</td>
    <td align="left">OVCAR3, OVCAR4</td>
    <td align="left">-</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      Prostate
     </bold> </td>
    <td align="left">-</td>
    <td align="left">PC3, DU145</td>
    <td align="left">-</td>
    <td align="left">-</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      Renal
     </bold> </td>
    <td align="left">-</td>
    <td align="left">786-0, RXF-393</td>
    <td align="left">A498, ACHN, CAKI-1, SNC12C, TK10, U031</td>
    <td align="left">-</td> 
   </tr> 
   <tr> 
    <td align="left"> 
     <bold>
      Unknown
     </bold> </td>
    <td align="left">ADR-RES</td>
    <td align="left">-</td>
    <td align="left">-</td>
    <td align="left">-</td> 
   </tr> 
  </tbody> 
 </table> 
 <table-wrap-foot> 
  <p>The 60 cell lines reorganized in 4 categories, as described in the text, on the basis of the most representative mutation of each cell line: </p> 
  <p>Cell lines carrying mutations able to interfere with Ras-Raf-MAPK pathway (i.e., mutations in genes encoding Ras, B-Raf, ERBB2, PDGFRA, referred to as Ras);</p> 
  <p>Cell lines carrying mutations able to interfere with PI3K-Akt pathway (i.e., mutations in genes encoding PI3KCA, PTEN and Lkb1, referred to as PI3K);</p> 
  <p>Cell lines carrying no somatic mutations interfering with the two above pathways (i.e., mutations in genes encoding for CDKN2A, p53, referred to as Other Mutation);</p> 
  <p>Cell lines for which the presence of somatic mutations interfering with the two above pathways has not been searched, referred to as Not Tested.</p> 
 </table-wrap-foot> 
</table-wrap>